WESTLAKE VILLAGE, Calif., March 19, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it will host a 2015 Outlook investor call and webcast at 4:30 p.m. ET on Thursday, March 26, 2015.
Individuals interested in participating in the call should dial (877) 344-3890 (U.S. and Canada) or (760) 666-3770 (international) using conference ID number 11359260. To access the webcast, please visit the Investors section of KYTHERA's website at www.kythera.com.
The call will be available for replay via telephone starting March 26, 2015, at approximately 5:30 p.m. ET, running through 11:59 p.m. ET on April 2, 2015. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 11359260. The archived webcast will be available on KYTHERA's website for seven days beginning approximately one hour after the call has completed.
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA's lead product candidate, ATX-101, is currently in late-stage clinical development as an injectable treatment for the improvement of submental fullness, which commonly presents as a double chin, and is a potential first-in-class submental contouring injectable drug. The FDA has determined the NDA will have a Prescription Drug User Fee Act (PDUFA) action date of May 13, 2015. In addition to its lead product candidate ATX-101, KYTHERA also licensed the worldwide rights to setipiprant, an early-stage potential treatment for hair loss. KYTHERA also maintains an active research interest in fat biology, pigmentation modulation and facial contouring.
CONTACT: Investor Contact: Heather Rowe Director, Investor Relations Tel: (818) 587-4559 email@example.com
Source:KYTHERA Biopharmaceuticals, Inc.